Proteomics is advancing at a rapid pace, driven by breakthroughs in technology and increasing demand for deeper biological insights. With its potential to revolutionize drug discovery, diagnostics, and personalized medicine, proteomics is emerging as a key frontier in life sciences.

Proteomic studies today resemble isolated islands. Each built on unique sample handling, analytical platforms, and data processing pipelines. Whether using MS-based workflows like DDA/DIA or affinity-based platforms such as PEA and SOMAmers, the lack of shared reference materials makes it nearly impossible to compare results across studies.

This fragmentation leads to missed opportunities. Valuable insights remain locked within datasets that cannot be integrated, and reproducibility suffers. For researchers and clinicians alike, this means slower progress toward reliable biomarkers and personalized medicine.

A Practical and Scalable Solution

Published today in Nature Genetics, a paper by Tiannan Guo , Jennifer Van Eyk, PhD, Jochen Schwenk, Uwe Völker, and the HUPO community, proposes a practical and scalable solution: standardized reference materials. These donor-derived or synthetic plasma samples, spiked with isotopically labeled proteins, serve as universal benchmarks. By incorporating them into every experimental batch, researchers can normalize data across platforms and time points, enabling robust meta-analyses and reproducible findings .

At Evosep, we are deeply aligned with its core message: Standardization is essential for unlocking the full potential of proteomic data.

Evosep’s high-throughput, standardized workflows are uniquely positioned to support this initiative. Our systems are designed for consistency, scalability, and minimal sample handling variation, all of which is critical factors when integrating reference materials into routine proteomic analysis.

From Discovery to Clinical Impact

Standardization doesn’t just improve data quality. It transforms the entire technology pipeline. With shared references, we can:

• Enhance reproducibility across labs and studies.
• Accelerate biomarker validation by enabling direct comparisons.
• Support regulatory compliance for clinical applications.
• Lay the groundwork for AI-driven insights into the blood proteome.

As the paper notes, even a modest increase in measurement cost (~5%) is far outweighed by the benefits of data comparability and reliability

Evosep’s Commitment to the Future of Proteomics

As a contributor to this landmark publication and a leader in proteomics innovation, Evosep is committed to advancing standardization. At Evosep, we are proud to work with and support leading experts, including Tiannan Guo, Jennifer E. Van Eyk, Jochen M. Schwenk, Uwe Völker, and the HUPO community, whose recent publication in Nature Genetics sets a firm direction towards more standardization in proteomics workflows which is a pivotal step forward. We envision a future where proteomic data flows seamlessly across platforms, cohorts, and continents, driving faster discoveries and better outcomes for patients.

Standardization is not just technical refinement. It’s a strategic imperative for realizing the promise of precision medicine. Let’s build bridges that connect our proteomic islands and help unlock the full potential of the circulating blood proteome.

Read full paper in Nature Genetics here

Want to learn more?

Precision, reproducibility, scalability. Quantitative accuracy is the cornerstone of meaningful proteomics and in our upcoming webinar, we explore how targeted workflows are meeting these needs across complex samples like plasma and bioprocess matrices.

Join this week’s Evosep webinar to explore targeted workflows for confident quantification